Braxia Scientific (XCNQ:BRAX) Cash-to-Debt : 0.20 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Braxia Scientific Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Braxia Scientific's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.20.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Braxia Scientific couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Braxia Scientific's Cash-to-Debt or its related term are showing as below:

XCNQ:BRAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.2 Med: 74.87 Max: No Debt
Current: 0.2

During the past 3 years, Braxia Scientific's highest Cash to Debt Ratio was No Debt. The lowest was 0.20. And the median was 74.87.

XCNQ:BRAX's Cash-to-Debt is ranked worse than
91.82% of 1492 companies
in the Biotechnology industry
Industry Median: 6.85 vs XCNQ:BRAX: 0.20

Braxia Scientific Cash-to-Debt Historical Data

The historical data trend for Braxia Scientific's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Braxia Scientific Cash-to-Debt Chart

Braxia Scientific Annual Data

Trend

Mar21

Mar22

Mar23

Cash-to-Debt

102.79

39.99

7.06

Braxia Scientific Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial												7.01	7.06	4.37	1.09	0.20

Competitive Comparison of Braxia Scientific's Cash-to-Debt

For the Biotechnology subindustry, Braxia Scientific's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Braxia Scientific's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Braxia Scientific's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Braxia Scientific's Cash-to-Debt falls into.

Braxia Scientific Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Braxia Scientific's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.462	/	(0.076	+	0.131)
	=	7.06

Braxia Scientific's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.128	/	(0.136	+	0.501)
	=	0.20

Braxia Scientific (XCNQ:BRAX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Braxia Scientific Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Braxia Scientific's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Braxia Scientific (XCNQ:BRAX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Braxia Scientific Corp (XCNQ:BRAX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BRAXF:USA 4960:Germany

Address

700 Bay Street, Suite 1903, Toronto, ON, CAN, M5G 1Z6

Website

https://www.braxiascientific.com

Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

Braxia Scientific (XCNQ:BRAX) Headlines

No Headlines